Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug INCA036873 enters human trials for Hard-to-Treat cancers

NCT ID NCT07195916

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 6 times

Summary

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug through an IV, and researchers will monitor side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
INCA036873 (an experimental drug given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors and certain blood cancers that have not responded to prior therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of participants will receive the optimal dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * ECOG performance status of 0 or 1. * Histologically confirmed: * Clear cell renal cell carcinoma (ccRCC). * Diffuse large B-cell lymphoma (DLBCL, NOS). * High-grade B-cell lymphoma (HGBCL). * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). * Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement). * Disease progression, relapse, or refractory to prior therapy: * ccRCC: ≥1 prior line incl. ICI + TKI. * DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage. * PTCL/CTCL: ≥1 prior systemic therapy. * Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL). * Tumor tissue available for central testing. Exclusion Criteria: * Untreated or progressive CNS disease unless previously treated and stable. * Other active invasive malignancy within 2 years (except certain low-risk cancers). * Prior CD70-targeting therapy, including CAR T. * ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant. * Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions). * Primary immunodeficiency or active autoimmune disease requiring immunosuppression. * Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy. * Pregnancy, breastfeeding, or unwillingness to use effective contraception. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic large cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma diffuse large B-cell lymphoma hematopoietic and lymphoid system neoplasm high grade B-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides non-Hodgkin lymphoma nonpapillary renal cell carcinoma primary cutaneous T-cell non-Hodgkin lymphoma renal cell carcinoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancies Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    22 sites in 5 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Aarhus University Hospital

    NOT_YET_RECRUITING

    Aarhus, 08200, Denmark

  • Aou Policlinico S. Orsola-Malpighi

    NOT_YET_RECRUITING

    Bologna, 40138, Italy

  • Cancer Research Sa

    RECRUITING

    Adelaide, South Australia, 05000, Australia

  • Centro Ricerche Cliniche Di Verona

    NOT_YET_RECRUITING

    Verona, 37134, Italy

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • Cliniques Universitaires Ucl Saint-Luc

    RECRUITING

    Brussels, 01200, Belgium

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    NOT_YET_RECRUITING

    Milan, 20133, Italy

  • Macquarie University Hospital

    RECRUITING

    Sydney, New South Wales, 02109, Australia

  • Md Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

  • Peter Maccallum Cancer Centre-Royal Melbourne Hospital

    RECRUITING

    Melbourne, Victoria, 03000, Australia

  • Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

    NOT_YET_RECRUITING

    Rome, 00168, Italy

  • Princess Alexandra Hospital Australia

    RECRUITING

    Woolloongabba, Queensland, 04102, Australia

  • Rigshospitalet Uni of Hospital of Copenhagen

    RECRUITING

    Copenhagen, DK-2100, Denmark

  • Scri Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

  • Universitair Ziekenhuis Antwerpen

    RECRUITING

    Edegem, 02650, Belgium

  • Universitair Ziekenhuis Gent (Uz Gent)

    RECRUITING

    Ghent, 09000, Belgium

  • Universitair Ziekenhuis Leuven

    RECRUITING

    Leuven, 03000, Belgium

  • University of California San Diego Medical Center, Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Vanderbilt Medical Center

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.